Company intelligence / Profile preview
UBE Corporation
minato-ku, TOKYO, JAPANube.com ↗
- Ownership
- Private
- Employees
- ~9849
- Development stage
- Other
01
Overview
UBE has a track record of commercialized small molecule drugs such as betotastine besilate and prasugrel hydrochloride. The company is advancing new drug candidates in preclinical and clinical stages, including novel CDK7 inhibitors for oncology. It also provides contract manufacturing services for APIs and intermediates, with recent expansion into ADCs and oligonucleotide therapeutics.
- Therapeutic areas
- NeurologyDermatologyOncologyNephrologyImmunology
- Modalities
- Small moleculeAntibody-drug conjugateOligonucleotide therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kirilys Therapeutics(licensee of CDK7 inhibitor program)FRONTEO(AI-driven drug repositioning collaboration)
Beyond the preview
Go deeper on UBE Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UBE Corporation.